BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 16328028)

  • 21. Impressive regression of visceral and cerebral melanoma metastases under combination treatment including dacarbacine, radiotherapy and celecoxib.
    Becker MR; Gaiser T
    Int J Dermatol; 2009 Feb; 48(2):207-9. PubMed ID: 19200209
    [No Abstract]   [Full Text] [Related]  

  • 22. CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
    Kast RE; Karpel-Massler G; Halatsch ME
    Oncotarget; 2014 Sep; 5(18):8052-82. PubMed ID: 25211298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo.
    Ponthan F; Wickström M; Gleissman H; Fuskevåg OM; Segerström L; Sveinbjörnsson B; Redfern CP; Eksborg S; Kogner P; Johnsen JI
    Clin Cancer Res; 2007 Feb; 13(3):1036-44. PubMed ID: 17289900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intracranial inhibition of glioma cell growth by cyclooxygenase-2 inhibitor celecoxib.
    Nam DH; Park K; Park C; Im YH; Kim MH; Lee S; Hong SC; Shin HJ; Kim JH; Eoh W; McDonnell TJ
    Oncol Rep; 2004 Feb; 11(2):263-8. PubMed ID: 14719052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Celecoxib desensitization: continued temozolomide/celecoxib chemotherapy after a celecoxib-induced hypersensitivity reaction.
    Burbach GJ; Vajkoczy P; Zuberbier T
    Anticancer Drugs; 2012 Nov; 23(10):1118-20. PubMed ID: 23026982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells.
    Zhang R; Saito R; Shibahara I; Sugiyama S; Kanamori M; Sonoda Y; Tominaga T
    J Neurooncol; 2016 Jan; 126(2):235-42. PubMed ID: 26530267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
    Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H
    Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
    Reddy BS; Hirose Y; Lubet R; Steele V; Kelloff G; Paulson S; Seibert K; Rao CV
    Cancer Res; 2000 Jan; 60(2):293-7. PubMed ID: 10667579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study.
    Ferrandina G; Ranelletti FO; Legge F; Lauriola L; Salutari V; Gessi M; Testa AC; Werner U; Navarra P; Tringali G; Battaglia A; Scambia G
    Clin Cancer Res; 2003 Oct; 9(12):4324-31. PubMed ID: 14555502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
    Prados MD; Yung WK; Wen PY; Junck L; Cloughesy T; Fink K; Chang S; Robins HI; Dancey J; Kuhn J
    Cancer Chemother Pharmacol; 2008 May; 61(6):1059-67. PubMed ID: 17694310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats.
    Heimberger AB; Archer GE; McLendon RE; Hulette C; Friedman AH; Friedman HS; Bigner DD; Sampson JH
    Clin Cancer Res; 2000 Oct; 6(10):4148-53. PubMed ID: 11051269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
    Hau P; Kunz-Schughart L; Bogdahn U; Baumgart U; Hirschmann B; Weimann E; Muhleisen H; Ruemmele P; Steinbrecher A; Reichle A
    Oncology; 2007; 73(1-2):21-5. PubMed ID: 18332649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Temozolomide and treatment of malignant glioma.
    Friedman HS; Kerby T; Calvert H
    Clin Cancer Res; 2000 Jul; 6(7):2585-97. PubMed ID: 10914698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Finding drugs against CD133+ glioma subpopulations.
    Nakano I; Chiocca EA
    J Neurosurg; 2011 Mar; 114(3):648; discussion 648-50. PubMed ID: 21054138
    [No Abstract]   [Full Text] [Related]  

  • 35. [Chemopreventive effect of tamoxifen combined with celecoxib on DMBA-induced breast cancer in rats].
    Kang HF; Wang XJ; Liu XX; Dai ZJ; Xue FJ; Xue XH
    Ai Zheng; 2006 Nov; 25(11):1346-50. PubMed ID: 17094899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Inhibitive effect of celecoxib combined with tegafur gimeracil oteracil potassium on the growth of xenograft tumor of gastric cancer in nude mice].
    Meng C; Chen X; Luo Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 May; 29(5):458-61. PubMed ID: 23643260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.
    Narayanan BA; Reddy BS; Bosland MC; Nargi D; Horton L; Randolph C; Narayanan NK
    Clin Cancer Res; 2007 Oct; 13(19):5965-73. PubMed ID: 17908994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Plowman J; Waud WR; Koutsoukos AD; Rubinstein LV; Moore TD; Grever MR
    Cancer Res; 1994 Jul; 54(14):3793-9. PubMed ID: 8033099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.
    Chen X; Wang S; Wu N; Sood S; Wang P; Jin Z; Beer DG; Giordano TJ; Lin Y; Shih WC; Lubet RA; Yang CS
    Clin Cancer Res; 2004 Oct; 10(19):6703-9. PubMed ID: 15475461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy.
    Schönthal AH
    Neurosurg Focus; 2006 Apr; 20(4):E21. PubMed ID: 16709027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.